ALN-APP

DRUG2 trials

Sponsors

Alnylam Pharmaceuticals

Conditions

Cerebral Amyloid AngiopathyEarly-Onset Alzheimer Disease

Phase 1

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

RecruitingNCT05231785

Alnylam PharmaceuticalsEarly-Onset Alzheimer Disease

Start: 2022-02-04End: 2029-04-20Target: 60Updated: 2026-09-14

Phase 2

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

Active, not recruitingNCT06393712

Alnylam PharmaceuticalsCerebral Amyloid Angiopathy

Start: 2024-05-17End: 2029-12-14Updated: 2026-09-18

Related Papers

Small Interfering RNA Targeting Amyloid‐Beta Precursor Protein Reduces Alzheimer’s Disease Pathology in 5xFAD Mice

Alzheimer s & Dementia2025-12-01

Multiple‐Dose Results from an Ongoing Phase 1 Study of Mivelsiran, an Investigational RNA Interference Therapeutic Targeting Amyloid‐Beta Precursor Protein for Alzheimer’s Disease

Alzheimer s & Dementia2025-12-01

Single ascending dose results from an ongoing Phase 1 study of mivelsiran (ALN‐APP), the first investigational RNA interference therapeutic targeting amyloid precursor protein for Alzheimer’s disease

Alzheimer s & Dementia2024-12-016 citations

Interim phase 1 part A results for ALN‐APP, the first investigational RNAi therapeutic in development for Alzheimer’s disease

Alzheimer s & Dementia2023-12-0112 citations